Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

Btolz Jul. 15 at 2:57 PM

$ACRS Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases https://finance.yahoo.com/news/aclaris-therapeutics-begins-phase-1-125908645.html

0 · Reply

Bionco Jul. 15 at 12:23 PM

$ACRS How long will it take for Aclaris to regain the trust of retail investors after a series of trial failures?🤔

0 · Reply

Btolz Jul. 14 at 4:58 PM

$ACRS

0 · Reply

Bionco Jul. 14 at 3:57 PM

$ACRS is always shorted down after early morning run-up😠

1 · Reply

REALOSCAR Jul. 14 at 3:14 PM

$ACRS nice action today

0 · Reply

REALOSCAR Jul. 13 at 4:08 PM

$ACRS looks ready to push through $1.74 resistance 🔥 ▪️ Bullish wedge breakout setup 🧠 ▪️ MACD crossing upward 📈 ▪️ RSI building strength, room to run 🚀 ▪️ Holding higher lows – great accumulation zone 💰 Watching for that $1.74 break to confirm a move toward $1.90+ Volume picking up slowly — this one could squeeze soon 💥

0 · Reply

PepCF Jul. 13 at 3:46 PM

$ACRS When will this go to the moon?” 🚀📈

0 · Reply

Bionco Jul. 13 at 2:02 AM

$ACRS In the latest corporate presentation, the company stated that it has received the safety and efficacy results from the ATI-2138 POC trial and is currently awaiting the full set of pharmacodynamic data. ATI-2138 is still considered one of its potential best-in-class assets. Does that imply the POC trial achieved "a compelling efficacy"?

1 · Reply

Bionco Jul. 12 at 10:40 PM

$ACRS I see no reason ATI-2138 will fail unless the data below is false or inaccurate! PK data comparison of ATI-2138 vs Ritlecitinib Tmax: 0.5–1.5 hrs vs ~1 hrs t1/2: 1.5–2.3 hrs vs 1.3–2.3 hrs Steady-State: By day 7 or earlier vs day 4 PD Effects: ATI-2138: 44x potent inhibition in ITK than Ritlecitinib. ATI-2138: 5x potent inhibition in Jak3 than Ritlecitinib. Key Insight Despite near-identical PK profile, ATI-2138 offers significantly stronger and broader immune modulation by dual inhibition of ITK and JAK3, potentially delivering more robust efficacy in Th2/17-driven diseases compared to Ritlecitinib’s JAK3-focused mechanism. In addition, ATI-2138 demonstrates a favorable safety profile in healthy volunteers!

1 · Reply

Bionco Jul. 12 at 11:21 AM

$ACRS short interest was up. Some people bet on bad data coming!

2 · Reply

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 19 days ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 22 days ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

May 28, 2025, 9:20 AM EDT - 6 weeks ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 6:50 AM EDT - 2 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Mar 4, 2025, 7:00 AM EST - 4 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 5 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 5 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 6 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 7 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 8 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 8 months ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 8 months ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 8 months ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 8 months ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 10 months ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 1 year ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Sep 28, 2023, 7:18 AM EDT - 1 year ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

May 8, 2023, 11:56 AM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

May 8, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 2, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 9, 2023, 7:30 AM EST - 2 years ago

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

Feb 23, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Feb 9, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Jan 10, 2023, 4:04 PM EST - 2 years ago

Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower

Jan 6, 2023, 7:01 AM EST - 2 years ago

Aclaris Therapeutics Provides 2023 Outlook

Btolz Jul. 15 at 2:57 PM

0 · Reply

Bionco Jul. 15 at 12:23 PM

$ACRS How long will it take for Aclaris to regain the trust of retail investors after a series of trial failures?🤔

0 · Reply

Btolz Jul. 14 at 4:58 PM

$ACRS

0 · Reply

Bionco Jul. 14 at 3:57 PM

$ACRS is always shorted down after early morning run-up😠

1 · Reply

REALOSCAR Jul. 14 at 3:14 PM

$ACRS nice action today

0 · Reply

REALOSCAR Jul. 13 at 4:08 PM

0 · Reply

PepCF Jul. 13 at 3:46 PM

$ACRS When will this go to the moon?” 🚀📈

0 · Reply

Bionco Jul. 13 at 2:02 AM

1 · Reply

Bionco Jul. 12 at 10:40 PM

1 · Reply

Bionco Jul. 12 at 11:21 AM

$ACRS short interest was up. Some people bet on bad data coming!

2 · Reply

REALOSCAR Jul. 11 at 4:25 PM

$ACRS 6 👀

0 · Reply

Btolz Jul. 11 at 1:30 PM

$ACRS data coming....

0 · Reply

Bionco Jul. 11 at 12:23 PM

$ACRS Can Th2/Th17-related biomarkers be effectively targeted by ATI-2138 at the 10 mg BID regimen? The upcoming PD data will provide the answer! Just waiting 😺

0 · Reply

PepCF Jul. 11 at 8:31 AM

$ACRS

0 · Reply

Catchmeifucan82 Jul. 10 at 11:17 PM

$ACRS

0 · Reply

Catchmeifucan82 Jul. 10 at 11:06 PM

$ACRS. Anticipation play on data being released in July. Was supposed to be released in June. Got pushed back to July. Should hear the topline results sooner than later thus month Other anticipation plays entered before the run on expected upcoming PR's. $PROK Added at .58 cents. Hit $7.00+ $CGTX. Added .52 cents. Ran to over a $1.00 today. So keep an eye on ACRS...PR Incoming. Point is get in before the run. No chasing here. :)

1 · Reply

Bionco Jul. 10 at 10:29 PM

$ACRS the company is waiting for PD data.

0 · Reply